Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF

Ferdinando Nicoletti, Emanuela Mazzon, Paolo Fagone, Katia Mangano, Santa Mammana, Eugenio Cavalli, Maria Sofia Basile, Placido Bramanti, Giuseppe Scalabrino, Alois Lange, Francois Curtin

Research output: Contribution to journalArticle

Abstract

Epidermal growth factor (EGF)represents the prototype of the group I EGF family. The pleiotropic effects of the EGF have attracted attention to the possibility that it could be implicated in autoimmune diseases, such as Multiple Sclerosis (MS). We show here that treatment with EGF, as a late prophylactic regime, improved the clinical and histological features of EAE, a preclinical model of MS. In silico analysis further corroborated these findings by demonstrating that EGF receptors are less expressed in CNS from patients with MS as compared to controls. Taken together these data provide clear-cut in vivo proof of concept for a beneficial role of exogenously administered EGF in MS, that may, therefore, represent a novel therapeutic approach.

Original languageEnglish
Pages (from-to)224-232
Number of pages9
JournalJournal of Neuroimmunology
Volume332
DOIs
Publication statusPublished - Jul 15 2019

Keywords

  • EGF
  • Experimental allergic encephalomyelitis
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF'. Together they form a unique fingerprint.

  • Cite this